Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $6.43 + 0.28 (4.55%)
ExchangeNASDAQ
Volume26,136
Today's Open$6.19
Previous Close$6.15
Data as of 03/24/17 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $6.43 with a 52 week high of $9.95 and a 52 week low of $4.17.

Recent News

March 07, 2017

Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results

PLANO, Texas, March 07, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 30, 2016. Recent Highlights Completed FDA Premarket Approval and TUV CE mark submissions for Virtis™ Executed direct supply agreement with Minnetronix for Algovita® external devices Extended availability of the final two tranches of the $45 million debt facility U.S.

Read More >

March 06, 2017

Nuvectra to Present at the 29th Annual ROTH Conference

PLANO, Texas, March 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th Annual ROTH Conference in Dana Point, CA. Management will also be available for one-on-one meetings at the conference. Event:  29th Annual ROTH Conference Date:  Monday, March 13, 2017 Time:  1:0

Read More >


Investor Contact

The Ruth Group
Nick Laudico
Brian Johnston
investors@nuvectramed.com

Events
There are currently no events scheduled.